GlassScriptPhysician profile
Kenneth Naylor
NPI 1780658229
$1,630.68
in general payments reported to CMS, 2019-2025
26 companies · $46.72 in 2025
The $46.72 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $111 · 2021: $288 · 2022: $346 · 2023: $436 · 2024: $127 · 2025: $46.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $416.97 | 2021-2023 | Ligasure, Intellis Adaptivestim |
| Abbvie INC. | $335.31 | 2019-2023 | |
| Hologic Sales and Service, LLC | $142.35 | 2019-2024 | Coolseal Generator, Third Wave, Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $89.60 | 2019-2022 | |
| Astellas Pharma US INC | $76.83 | 2022-2024 | Veozah |
| Exeltis, USA INC. | $62.77 | 2020-2024 | Slynd |
| Axonics, INC. | $54.72 | 2023 | Axonics, Bulkamid |
| Daiichi Sankyo INC. | $50.53 | 2019-2022 | |
| Coopersurgical, INC. | $43.72 | 2022-2023 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $38.00 | 2019-2023 | Gardasil 9 |
| Channel Medsystems, INC. | $35.28 | 2023 | |
| Therapeuticsmd, INC. | $34.42 | 2019-2021 | |
| Pfizer INC. | $33.06 | 2022-2024 | |
| Biogen, INC. | $29.93 | 2025 | Zurzuvae |
| Organon LLC | $24.97 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $20.89 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.79 | 2025 | |
| Lsi Solutions INC | $15.49 | 2023 | Fornisee |
| Pharmacosmos Therapeutics INC. | $15.41 | 2024 | Monoferric |
| Radius Health, INC. | $14.76 | 2020 | |
| Smith+Nephew, INC. | $14.63 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $13.63 | 2020 | |
| Boston Scientific Corporation | $13.59 | 2019 | |
| Sumitomo Pharma America, INC. | $13.45 | 2024 | Myfembree |
| Novo Nordisk INC | $12.20 | 2019 | |
| Amgen INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Naylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.